Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

CSF markers for incipient Alzheimer's disease.

Blennow K, Hampel H.

Lancet Neurol. 2003 Oct;2(10):605-13. Review.

PMID:
14505582
[PubMed - indexed for MEDLINE]
2.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
[PubMed - indexed for MEDLINE]
3.

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K.

Acta Neurol Scand Suppl. 2003;179:47-51.

PMID:
12603251
[PubMed - indexed for MEDLINE]
4.

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.

Lancet Neurol. 2006 Mar;5(3):228-34. Erratum in: Lancet Neurol. 2006 Apr;5(4):293.

PMID:
16488378
[PubMed - indexed for MEDLINE]
5.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
[PubMed - indexed for MEDLINE]
6.

CSF biomarkers for mild cognitive impairment.

Blennow K.

J Intern Med. 2004 Sep;256(3):224-34. Review.

PMID:
15324365
[PubMed - indexed for MEDLINE]
7.

The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Engelborghs S, Le Bastard N.

Mol Diagn Ther. 2012 Jun 1;16(3):135-41. doi: 10.2165/11634170-000000000-00000.

PMID:
22646065
[PubMed - indexed for MEDLINE]
8.

Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Blennow K.

NeuroRx. 2004 Apr;1(2):213-25. Review.

PMID:
15717022
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

CSF tau and β-amyloid as biomarkers for mild cognitive impairment.

Hampel H, Blennow K.

Dialogues Clin Neurosci. 2004 Dec;6(4):379-90.

PMID:
22034251
[PubMed]
Free PMC Article
10.

[The role of CSF markers in the early diagnosis of Alzheimer's disease].

Vos SJ, Visser PJ, Verhey FR.

Tijdschr Psychiatr. 2011;53(9):647-53. Dutch.

PMID:
21898322
[PubMed - indexed for MEDLINE]
Free Article
11.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
[PubMed - indexed for MEDLINE]
12.

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H.

Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. Review.

PMID:
11831556
[PubMed - indexed for MEDLINE]
13.

Analysis of combined CSF biomarkers in AD diagnosis.

De Riva V, Galloni E, Marcon M, Di Dionisio L, Deluca C, Meligrana L, Bolner A, Perini F.

Clin Lab. 2014;60(4):629-34.

PMID:
24779297
[PubMed - indexed for MEDLINE]
14.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
[PubMed - indexed for MEDLINE]
15.

[Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].

Shoji M.

Brain Nerve. 2012 May;64(5):497-504. Review. Japanese.

PMID:
22570063
[PubMed - indexed for MEDLINE]
16.

Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.

Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.

J Alzheimers Dis. 2012;29(1):229-38. doi: 10.3233/JAD-2011-111349.

PMID:
22232006
[PubMed - indexed for MEDLINE]
17.

CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.

Blennow K, Vanmechelen E.

Brain Res Bull. 2003 Aug 15;61(3):235-42. Review.

PMID:
12909293
[PubMed - indexed for MEDLINE]
18.

CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.

Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K.

J Alzheimers Dis. 2010;22(4):1281-8. doi: 10.3233/JAD-2010-101293.

PMID:
20930282
[PubMed - indexed for MEDLINE]
19.

CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.

Andreasen N, Blennow K.

Clin Neurol Neurosurg. 2005 Apr;107(3):165-73. Review.

PMID:
15823670
[PubMed - indexed for MEDLINE]
20.

Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.

Malnar M, Kosicek M, Bene R, Tarnik IP, Pavelin S, Babic I, Brajenovic-Milic B, Hecimovic H, Titlic M, Trkanjec Z, Demarin I, Hecimovic S.

Acta Neurobiol Exp (Wars). 2012;72(3):264-71.

PMID:
23093013
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk